Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duocotexin
- Development stage
- Phase 4
- Lead developer
- Holley Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Duocotexin is a fixed-dose combination antimalarial drug containing dihydroartemisinin and piperaquine, manufactured by Holley Pharmaceutical. Dihydroartemisinin, an artemisinin derivative, acts rapidly by generating reactive oxygen species and carbon-centered radicals upon activation by heme within the malaria parasite, potentially inhibiting the Sarco/endoplasmic reticulum Ca2+-ATPase (PfATP6). Piperaquine is a long-acting bisquinoline that interferes with the parasite's detoxification of heme into hemozoin. This combination is indicated for the treatment of uncomplicated malaria caused by *Plasmodium falciparum* and *Plasmodium vivax*. The University of California, San Francisco (UCSF) sponsored the DPART study to investigate the pharmacokinetics and safety of Duocotexin in HIV-infected children receiving various antiretroviral therapies, addressing potential drug-drug interactions.
- Brand names
- Duocotexin
- Other names
- dihydroartemisinin-piperaquineDPdihydroartemisinin + piperaquine
02
Targets
PfFV heme (Plasmodium falciparum food vacuole heme)
Beyond the preview
Go deeper on Duocotexin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Duocotexin.